Eli Lilly and Co. has filed a patent for RET kinase inhibitors, which are compounds used in the treatment of diseases associated with RET kinase. The patent also covers pharmaceutical compositions and methods of using these inhibitors. GlobalData’s report on Eli Lilly and Co gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eli Lilly and Co - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eli Lilly and Co, Cancer treatment biomarkers was a key innovation area identified from patents. Eli Lilly and Co's grant share as of September 2023 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230312544A1) describes a compound of a specific formula and its various derivatives. The compound is intended for use in the treatment of cancer, particularly RET-associated cancers. The patent claims cover the compound itself, as well as its various forms and pharmaceutical compositions.

The compound described in the patent has a specific chemical formula, and the claims provide additional details about the compound's structure. The claims also specify different variations of the compound, including different substituents and functional groups. These variations are intended to enhance the compound's effectiveness and suitability for treating cancer.

The patent claims also cover the use of the compound in the treatment of cancer, specifically RET-associated cancers. RET-associated cancers include lung cancer, thyroid cancer (including papillary, medullary, and differentiated thyroid cancer), breast cancer, colorectal cancer, renal cell carcinoma, and cervical cancer, among others. The claims highlight the potential of the compound to be effective in treating these types of cancer.

In addition to the compound itself, the patent claims also cover pharmaceutical compositions containing the compound. These compositions may include one or more pharmaceutically acceptable carriers, diluents, or excipients. The inclusion of these additional components is intended to ensure the compound's stability, efficacy, and safety when administered to patients.

Overall, the patent claims describe a compound and its various derivatives that have potential applications in the treatment of cancer, particularly RET-associated cancers. The claims provide specific details about the compound's structure and variations, as well as its use in pharmaceutical compositions. This patent filing represents a significant development in the field of cancer treatment and may have implications for future research and drug development efforts.

To know more about GlobalData’s detailed insights on Eli Lilly and Co, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies